- Financial highlights
- Cash and cash equivalents amounted to EUR 209 million as of June 30, 2022
- The net loss in the first half of 2022 was 10 million euros
- developments in our programs
- Patient recruitment for the double-blind portion of the phase 3 study in primary biliary cholangitis (PBC) ELATIVETM Completed at the end of the first semester of 2022
- Orphan drug status for GNS561 for the treatment of cholangiocarcinoma
- AAgreement signed to acquire clinical-stage biotechnology company Versantis, further solidifying GENFIT’s position as a leader in Acute-on-Chronic Liver Failure (ACLF).
- Expanded pipeline with six ongoing programs in five rare liver indications
Lille (France), Cambridge, MA; September 28, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients suffering from severe and chronic liver disease, today announced its financial results for the first half of 2022 and provided a company update.
The half-year business and financial report is publicly available and was filed today with the French Autorité des Marchés Financiers (French Financial Markets Authority) and filed with the US Securities and Exchange Commission. The condensed consolidated financial statements are included in this press release and the full financial statements are available on the Investors page of the GENFIT website.
Pascal Prigent, CEO of GENFIT commented:
«I am very pleased with the way GENFIT has pursued the execution of its strategy in 2022 in line with the plan announced in Fall 2020 and our ambitions. Today we have a broad and diversified pipeline of promising programs in rare and severe liver diseaseshe diseases characterized by a high unmet medical need. Thanks to the acquisition of Versantis, which is about to close, we will soon have six ongoing programs at all stages of development – pre-clinical, phase 1, phase 2 and phase 3 – in five different indications. That should us…
